Stoke Therapeutics: Treatment outcomes of STK-001 for Dravet syndrome

In this video, Dr Scott Perry, MD of Cook Children’s Medical Center presents data from multiple ongoing clinical studies that support the potential of STK-001, an antisense oligonucleotide, as the first disease-modifying treatment for Dravet syndrome. This presentation was recorded at the 2023 International Epilepsy Congress. For additional information about STK-001 or Stoke Therapeutics, please contact Stoke Therapeutics at Medicalinformation@stoketherapeutics.com or visit www.stoketherapeutics.com/